



UNIVERSITÀ DEGLI STUDI DI SALERNO

Facoltà di Ingegneria
Dipartimento di Ingegneria Industriale
Corso di Laurea in Ingegneria Chimica

Modeling the drug release from HPMC tablets with different macrostructure

Master thesis in:
Transport Phenomena

Supervisor:

Prof. Ing. Lamberti Gaetano

Prof. Ing. Anette Larsson

Ing. Diego Caccavo

Candidate:

Manuela Espresso

matricola 0622200775

Anno Accademico 2019/2020



Part of this work has been performed in partnership with the Chalmers University of Technology in Goteborg, under the supervision of Prof. Anette Larsson.

To my mam and dad

Questo testo è stato stampato in proprio, in (font adoperato)

La data prevista per la discussione della tesi è il (data di laurea)
Fisciano, (data di stampa)

Table of contents

Table of contents.....	I
List of figures	<u>IVVIII</u>
List of tables	<u>XXVIII</u>
Abstract	<u>XIIXXI</u>
Introduction	<u>1423</u>
1.1 3D Printing in the pharmaceutical field _____	<u>1524</u>
1.1.1 Semi solid extrusion	<u>1625</u>
1.1.2 FDM and the importance of the filament properties	<u>1827</u>
1.1.3 Hydrogels and their poroviscoelastic behavior	<u>2029</u>
1.1.3 HydroxyPropyl MethylCellulose (HPMC)	<u>2231</u>
1.2 State of art _____	<u>2332</u>
1.2.1 Tablets with different infill	<u>2433</u>
1.2.2 Tablets with different pattern of infill	<u>3039</u>
1.2.3. Tablets with different macrostructure	<u>3039</u>
1.3 Mechanistic description _____	<u>3241</u>
1.3.1 Diffusion in hydrogels	<u>3443</u>
1.4 Empirical models _____	<u>3443</u>
1.5 Aims _____	<u>3746</u>
Modeling.....	<u>3948</u>
2.1 Balance equations _____	<u>4049</u>

2.1.1 Mass balance	<u>4049</u>
2.1.2 Linear momentum balance	<u>4049</u>
2.1.3 Volumetric constraint	<u>4149</u>
2.2 Constitutive equations _____	<u>4150</u>
2.2.1 The elastic contribution	<u>4254</u>
2.2.2 The mixing contribution	<u>4453</u>
2.2.3 The total free energy density	<u>4554</u>
2.3 The initial conditions _____	<u>4958</u>
2.4 Implementation _____	<u>4958</u>
2.5 Free swelling test _____	<u>5160</u>
2.5.1 Tablet with homogeneously distributed drug	<u>5264</u>
2.5.2 Tablet with the drug in the outside layer	<u>5362</u>
2.5.3 Tablet with the drug in the inside layer	<u>5463</u>
2.5.4 Pulsatile Tablet	<u>5564</u>
2.5.5 Optimization	<u>5665</u>
2.5.4.a Setting up the optimization on COMSOL software	<u>5867</u>
2.5.4.b Optimization for Parameter estimation	<u>5867</u>
Results and discussion	<u>5969</u>
3.1. Optimization Results _____	<u>6070</u>
3.2 Tablet with homogeneously distributed drug _____	<u>6174</u>
3.2.1 Parametric Sweep results	<u>6676</u>
3.3 Tablet with drug in the outside layer _____	<u>7488</u>
3.3.1 Sweep parametric results	<u>7794</u>
3.4 Tablet with drug in the inside layer _____	<u>86404</u>
3.4.1 Sweep parametric results	<u>90405</u>
3.5 Pulsatile tablet _____	<u>99414</u>
3.5.1 Sweep parametric results	<u>102446</u>
3.6 Comparison between different macrostructures _____	<u>110423</u>
Conclusions	<u>112427</u>

4.1 Conclusion _____ 113128

References 114129

List of figures

Figure 1: Schematic of the combination of HME and 3D process [1]	15
Figure 2: Schematic of typical extruder system. [4]	17
Figure 3: Schematic of typical 3D printing system [7]	18
Figure 4: Filament properties during 3D printing process. (a) filament too brittle, (b) filament good for printing, (c) filament too soft [8]	19
Figure 5: Schematic representation of two modes of deformation in a gel.....	20
Figure 6:A schematic representation of a partially swollen drug delivery system with the erosion, diffusion and swelling front.	22
Figure 7: HPMC structure [15]	23
Figure 8:Materials used in 3D printer [9]	24
Figure 9:Dissolution profiles of 3DP tablets with varying infill percentages in modified Hank's buffer (pH 6.8) [10].....	25
Figure 10:In vitro drug release profiles at (a) pH 2 and (b) pH 6.8 from physical mixtures, crushed extrudates, and 3D printed tablets (100% and 60% infill) containing 10:45:45 w/w haloperidol-Kollidon® VA64-Affinisol™ 15 cP mixtures (10% w/w haloperidol) [3].....	26
Figure 11 : Dissolution profiles of 3DP 5-ASA and 4-ASA tablets with varying infill percentages in modified Hank's buffer (pH 6.8) [11]	27
Figure 12: Drug release profiles of tablets (T) with shells 1.6 mm thickness and different infill percentages(black squares infill percentages=100%, red circles infill percentages=80% and green triangles infill percentages=20%)[2]	28
Figure 13:On the top, tablet with different infill, on the bottom, drug release profiles of tablet as infill density increases [12]	29
Figure 14:On top left, tablet with different pattern of infill, on the bottom, drug release profiles of tablet [12]	30
Figure 15:On the left, the cross-section of tablet, on the right the drug release profile at different shell dimension [12]	31
Figure 16: on the left, the cross-section of table, on the right the drug release profile [12].....	32
Figure 17:Schematic illustrating the different zones of diffusion, function of the Temperature and Penetrant concentration [13].....	33

Figure 18: The chain displacement vector and the spatial configuration of a polymer chain taking the origin of coordinates at one end of the chain [RIF]. ..42	
Figure 19: Sketch of the dry network, reference, and current configuration46	
Figure 20: The elastic modulus as water fraction increases51	
Figure 21: Computational domain. With Γ are indicated the domain boundaries.52	
Figure 22: 1D-axisymmetric geometry of a tablet in with the drug is in the outside layer (Ω_1).....53	
Figure 23: 1D-axisymmetric geometry of a tablet in with the drug is in the inside layer (Ω_1)..... <u>5554</u>	
Figure 24: 1D-axisymmetric geometry of a pulsatile tablet in with the drug is in the first (Ω_1) and second domain (Ω_2)...... <u>5655</u>	
Figure 24: Schematic of the control variables and the objective function..... <u>5756</u>	
Figure 25: Definition of control variable in Comsol Software <u>5857</u>	
Figure 26: the optimization results starting from the literature date.....60	
Figure 27: Water mass absorbed at different dissolution times for the tablet with the drug homogenously distributed62	
Figure 28: a) the drug mass versus the dissolution time; b) the drug release versus the dissolution time for the tablet with the drug homogenously distributed.....63	
Figure 29: Water concentration profiles along the radius of the tablet at different times (0, 1,2,3,4 and 5h) for the tablet with the drug homogenously distributed..... <u>6463</u>	
Figure 30: Drug concentration profiles at different time (0,1,2 3,4 and 5 h) for the tablet with the drug homogenously distributed..... <u>6564</u>	
Figure 31: a) Water and b) drug concentration profiles at different D1 values (blue full line D1=5E-8 [m ² /s], red dashed line D1=2.52e-7 [m ² /s], green line with alternating dots and dashed D1=5e-7 [m ² /s] at 2 h of dissolution for the tablet with the drug homogenously distributed <u>6665</u>	
Figure 32: The effect of the water on the drug diffusivity profiles at different beta1 value (red line beta1=4, green line beta1=5, purple line beta1=6)..... <u>6766</u>	
Figure 33: a) Water mass and b) drug release profiles at different D1 values (blue full line D1=5E-8[m ² /s], red dashed line D1=2.52e-7, green line with alternating dots and dashed D1=5e-7[m ² /s]) for the tablet with the drug homogenously distributed <u>6766</u>	
Figure 34: a) Water and b) drug concentration profiles at different beta1 values (blue full line beta1=5, red dashed line beta1=5.59, green line with alternating dots and dashed beta1=7) at 2 h of dissolution for the tablet with the drug homogenously distributed <u>6867</u>	

- Figure 35: a) Water mass and b) drug release profiles at different β_1 (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating dots and dashed $\beta_1=7$) for the tablet with the drug homogeneously distributed [6968](#)
- Figure 36: The diffusivity D_1 vs w_1 [7069](#)
- Figure 37: Water and b) drug concentration profiles at different D_3 values (blue full line $D_3=2E-8[m^2/s]$, red dashed line $D_3=8.15E-8[m^2/s]$, green line with alternating dots and dashed $D_3=2E-7[m^2/s]$) at 2 h of dissolution for the tablet with the drug homogeneously distributed..... [7069](#)
- Figure 38: a) Water mass and b) drug release profiles at different D_3 values (blue full line $D_3=5E-13[m^2/s]$, red dashed line $D_3=1E-12[m^2/s]$, green line with alternating dots and dashed $D_3=5E-12[m^2/s]$) for the tablet with the drug homogeneously distributed..... [7170](#)
- Figure 39: Water and b) drug concentration profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution for the tablet with the drug homogeneously distributed..... [7271](#)
- Figure 40: a) Water mass and b) drug release profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution [7271](#)
- Figure 41: Water mass absorbed at different dissolution times for the tablet with the drug distributed in the shell..... [7473](#)
- Figure 42: a) the drug mass versus the dissolution time; b) the drug release versus the dissolution time for the tablet with the drug distributed in the shell..... [7573](#)
- Figure 43: Water concentration profiles along the radius of the tablet at different times (0, 1,2 and 3h) for the tablet with the drug distributed in the shell..... [7574](#)
- Figure 44: Drug concentration profiles at different time (0, 1,2 and 3 h) for the tablet with the drug distributed in the shell..... [7674](#)
- Figure 45: a) Water and b) drug concentration profiles at different D_1 values (blue full line $D_1=5E-8 [m^2/s]$, red dashed line $D_1=2.52e-7 [m^2/s]$, green line with alternating dots and dashed $D_1=5e-7 [m^2/s]$) at 2 h of dissolution for the tablet with the drug distributed in the shell..... [7776](#)
- Figure 46:a) Water mass and b) drug release profiles at different D_1 values (blue full line $D_1=5E-8[m^2/s]$, red dashed line $D_1=2.52e-7$, green line with alternating dots and dashed $D_1=5e-7[m^2/s]$) for the tablet with the drug distributed in the shell..... [7877](#)
- Figure 47: a) Water and b) drug concentration profiles at different β_1 values (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating dots and dashed $\beta_1=7$) at 2 h of dissolution for the tablet with the drug distributed in the shell..... [7978](#)

Figure 48: a) Water mass and b) drug release profiles at different β_1 (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating dots and dashed $\beta_1=7$) for the tablet with the drug distributed in the shell8079

Figure 49: Water and b) drug concentration profiles at different D_3 values (blue full line $D_3=2E-8$ [m²/s], red dashed line $D_3=8.15E-8$ [m²/s], green line with alternating dots and dashed $D_3=2E-7$ [m²/s]) at 2 h of dissolution for the tablet with the drug distributed in the shell8180

Figure 50: a) Water mass and b) drug release profiles at different D_3 values (blue full line $D_3=2E-8$ [m²/s], red dashed line $D_3=8.15E-8$ [m²/s], green line with alternating dots and dashed $D_3=2E-7$ [m²/s]) for the tablet with the drug distributed in the shell8280

Figure 51: Water and b) drug concentration profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution.....8384

Figure 52: a) Water mass and b) drug release profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution.....8382

Figure 53: a) Water and b) drug concentration profiles at different shell size (blue full line shell size=4mm, red dashed line shell size=2.5mm and blue sky line with alternating dots and dashed shell size=1mm) at 1 h of dissolution..8483

Figure 54: a) Water mass and b) drug release at different shell size (blue full line shell size=4mm, red dashed line shell size=2.5mm and blue sky line with alternating dots and dashed shell size=1mm) at 1 h of dissolution.....8584

Figure 55: Water mass absorbed at different dissolution times for the tablet with the drug distributed in the core8685

Figure 56: the drug mass versus the dissolution time; b) the drug release versus the dissolution time for the tablet with the drug distributed in the core8785

Figure 57: Water concentration profiles along the radius of the tablet at different times (0, 1,2,3,4 and 5 h) for the tablet with the drug distributed in the core .8886

Figure 58: Drug concentration profiles along the radius of the tablet at different times (0, 1,2,3,4 and 5h) for the tablet with the drug distributed in the core .8987

Figure 59: a) Water and b) drug concentration profiles at different D_1 values (blue full line $D_1=5E-8$ [m²/s], red dashed line $D_1=2.52E-7$, green line with alternating dots and dashed $D_1=5E-7$ [m²/s]) at 2 h of dissolution for the tablet with the drug distributed in the core9088

Figure 60: A) Water mass and b) drug release profiles at different D_1 values, on the right drug release profiles at different D_1 (blue full line $D_1=5E-8$ [m²/s], red dashed line $D_1=8.15E-8$, green line with alternating dots and dashed $D_1=5E-7$ [m²/s]) for the tablet with the drug distributed in the core9189

Figure 61: a) Water and b) drug concentration profiles at different β_1 values (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating

dots and dashed $\beta_1=7$) at 2 h of dissolution for the tablet with the drug distributed in the core	<u>9290</u>
Figure 62: a) Water mass and b) drug release profiles at different β_1 (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating dots and dashed line $\beta_1=7$) for the tablet with the drug distributed in the core	<u>9394</u>
Figure 63: Water and b) drug concentration profiles at different D_3 values (blue full line $D_3=2E-8[m^2/s]$, red dashed line $D_3=8.15E-8[m^2/s]$, green line with alternating dots and dashed $D_3=2E-7[m^2/s]$) at 2 h of dissolution for the tablet with the drug distributed in the core	<u>9494</u>
Figure 64: a) Water mass and b) drug release profiles at different D_3 values (blue full line $D_3=2E-8[m^2/s]$, red dashed line $D_3=8.15E-8[m^2/s]$, green line with alternating dots and dashed $D_3=2E-7[m^2/s]$)	<u>9492</u>
Figure 65: Water and b) drug concentration profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution for the tablet with the drug distributed in the core	<u>9593</u>
Figure 66: a) Water mass and b) drug release profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution for the tablet with the drug distributed in the core	<u>9694</u>
Figure 67: a) Water and b) drug concentration profiles at different core size (blue full line core size=4mm red dashed line core size=2.5mm blue sky line with alternating dots and dashed core size=0.2mm) at 3 h of dissolution	<u>9795</u>
Figure 68: a) Water mass and b) drug release at different core size (blue full line core size=4mm red dashed line core size=2.5mm blue sky line with alternating dots and dashed core size=0.2mm) at 3 h of dissolution.....	<u>9896</u>
Figure 69: Water mass absorbed at different dissolution times for pulsatile tablet	<u>9997</u>
Figure 70: the drug mass versus the dissolution time; b) the drug release versus the dissolution time for the pulsatile tablet	<u>10097</u>
Figure 71: Water concentration profiles along the radius of the tablet at different times (0, 1,2,3,4 and 5h) for the pulsatile tablet.....	<u>10198</u>
Figure 72: Drug concentration profiles along the radius of the tablet at different times (0, 1,2,3,4 and 5h) for the pulsatile tablet.....	<u>10298</u>
Figure 73: a) Water and b) drug concentration profiles at different D_1 values (blue full line $D_1=5E-8[m^2/s]$, red dashed line $D_1=2.52e-7$, green line with alternating dots and dashed $D_1=5e-7[m^2/s]$) at 2 h of dissolution for the pulsatile tablet.....	<u>10399</u>
Figure 74: a) Water mass and b) drug release profiles at different D_1 values, on the right drug release profiles at different D_1 (blue full line $D_1=5E-8[m^2/s]$, red dashed line $D_1=2.52e-7$, green line with alternating dots and dashed $D_1=5e-7[m^2/s]$) for the pulsatile tablet.....	<u>103400</u>

Figure 75: a) Water and b) drug concentration profiles at different β_1 values (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating dots and dashed $\beta_1=7$) at 2 h of dissolution for the pulsatile tablet. ~~104100~~

Figure 76: a) Water mass and b) drug release profiles at different β_1 (blue full line $\beta_1=5$, red dashed line $\beta_1=5.59$, green line with alternating dots and dashed line $\beta_1=7$) for the pulsatile tablet ~~105101~~

Figure 77: Water and b) drug concentration profiles at different D_3 values (blue full line $D_3=5E-13[m^2/s]$, red dashed line $D_3=1E-12[m^2/s]$, green line with alternating dots and dashed $D_3=5E-12[m^2/s]$) at 12 h of dissolution for the pulsatile tablet ~~105102~~

Figure 78: On the left water mass profiles, on the right drug release profiles at different D_3 values (blue full line $D_3=5E-13[m^2/s]$, red dashed line $D_3=1E-12[m^2/s]$, green line with alternating dots and dashed $D_3=5E-12[m^2/s]$) ~~106102~~

Figure 79: Water and b) drug concentration profiles at different β_3 values (blue full line $\beta_3=12$ red dashed line $\beta_3=13.04$ green line with alternating dots and dashed $\beta_3=14$) at 2 h of dissolution for the pulsatile tablet ~~107103~~

Figure 80: a) Water mass and b) drug release profiles at different β_3 values (blue full line $\beta_3=4$ red dashed line $\beta_3=5$ green line with alternating dots and dashed $\beta_3=6$) at 12 h of dissolution for the pulsatile tablet ~~107104~~

Figure 81: a) Water and b) drug concentration profiles at different shell and core size (red dashed which represents shell and core size reduction, blue line with alternating dots and dashed which represents shell and core size increase, purple line with alternating dots which represents original tablet) at 1 h of dissolution ~~108104~~

Figure 82: a) Water mass and b) drug release at different shell and core size (red dashed which represents shell and core size reduction, blue line with alternating dots and dashed which represents shell and core size increase, purple line with alternating dots which represents original tablet) at 1 h of dissolution ~~109105~~

Figure 83: Drug release profiles of different models (blue full line=Drug homogenous, red dashed line=Drug in the shell, green line with alternating dots and dashed= Drug in the core and blue sky line with alternating dots and dashed=Pulsatile Tablet) ~~110106~~

Figure 84: Comparison between experimental and calculated results in the model ~~Errore. Il segnalibro non è definito.~~107

List of tables

Table 1: The parameters implemented in the model. **Errore. Il segnalibro non è definito.**⁵⁶

Table 2: The Parameters obtained from the comparison between the model and experimental results **Errore. Il segnalibro non è definito.**⁸⁹

Abstract

Using 3D printing, it is possible to design and develop complex dosage forms that can be suitable for tuning drug release. It, indeed, allows a flexible variation of the drug dose, release characteristics, or implementation of combinations of several drugs in the same dosage form to correspond to the individual patient needs. Polymers are the key materials that are necessary for 3D printing and it is important to understand which polymers are suitable for extrusion-based 3D printing of pharmaceuticals.

With 3D printer disc with different infill, disc with different pattern of infill and disc with different macrostructure can be printed. Discs with different macrostructure have been studied in order to analyze how different macrostructure impact on the drug release.

When a network of long polymers is immersed in a physiological fluid, this starts to penetrate inside the polymeric hydrophilic matrix. When a certain solvent concentration is reached, the polymeric chains unfold due to a glass-rubber transition, and a gel layer is formed. In the swollen region, the drug molecules can diffuse toward the dissolution medium, once they are dissolved.

In order to consider the hydrogel mechanics, the pure hydrogel behavior has been studied. Hydrogels normally couple solvent mass transport to system deformation and vice versa. This phenomenon is generally called poroelasticity and it is characteristic also of other materials. This complex behavior, generally defined “poroviscoelastic”, is the sum of a poroelastic and a viscoelastic behavior. The first is due to long-range motion of the water molecules, which can enter (swelling) or leave (shrinking) the system or move within the system (isochoric deformation). The viscoelasticity, instead, is mainly a characteristic of the polymeric structure, which can rearrange its spatial configuration (i.e. by the breakage and reformation of cross-links) and respond with

a time dependent mechanical behavior. The full understanding of this behavior is crucial to correctly design such complex systems.

The aim of this thesis is to simulate thought poroelastic modeling, the drug release from tablets of HPMC hydrogel with different macrostructures that will be printed using 3D printer. In this thesis, the monophasic approach, which is more consistent, has been chosen. This model considered hydrogel as single-phase matter, in which several components can coexist and therefore the properties are not of the single phase but of the combination of all the species.

The simulation has been done with the software COMSOL Multiphysics 5.2. This software is able to resolve the Partial Different Equations (PDEs) that describe the system, through the Finite Element Method (FEM). The work can be divided in two parts. In the first part the mathematical models of the tablet with different macrostructure have been studied and implemented in the software, at this point the sweep parametric has been executed in order to understand how the parameters impact system.

In the second part, since different models have been studied, the comparison between them has been done in order to understand how the macrostructure impacted the system.

References

1. Zhang, J; Feng, X; Patil, H; Tiwari, R; Repka, M, Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets, *Journal of Pharmaceutical Sciences*, 186 (2016).
2. Zhanga, J; Yangb, W; Anh Q. Voa, Fenga, X; Yea, X; Kima, D; Repka, M, Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: Structure and drug release correlation, *Carbohydrate polymers*, 177(2017).
3. Solanki; Tahsin, Md; Shah, A; Serajuddin, A, Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability, *Journal of Pharmaceutical Sciences*, 107 (2018).
4. Patil, H; Tiwari, R; Repka, M; Hot-Melt Extrusion: from Theory to Application in Pharmaceutical Formulation, *PharmSciTech*,17(2016).
5. Repka, M; Shah, S; Lu, j; Maddineni, S; Morott, J, Melt extrusion: process to product, *Expert Opin, Drug Deliv*,9(2012).
6. Azad, M; Olawuni, D; Kimbell, G; Badruddoza, A; Hossain, S and Sultana, T, Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holist Materials-Process Perspective, *Pharmaceutics*,12(2020).
7. Aho, J.; Bøtker, J. P.; Genina, N.; Edinger, M; Arnfast, L.; Rantanen, J; Roadmap to 3D-Printed Oral Pharmaceutical Dosage Forms: Feedstock Filament Properties and Characterization for Fused Deposition Modeling, *Journal of Pharmaceutical Sciences*, 108 (2019).
8. Zhanga, J; Fenga, X; Patil, H; Tiwari, R; Repka, M, Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets, *International Journal of Pharmaceutics* 519 (2017).
9. Melocchi, A; Parietti, F; Maroni, A; Foppoli, A; Gazzanica, A; Zema, L, Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling, *International Journal of Pharmaceutics* 509 (2016).

10. Goyanes, A; Buanz, A; Basit, A; Gaisford, S, Fused-filament 3D printing (3DP) for fabrication of tablets, *International Journal of. Pharmaceutics*,476(2014).
 11. Goyanes, a; Buanz, A; Hatton, G; Gaisford, S; Basit, 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets,*Eur J Pharm Biopharm*,89(2015).
 12. Kadrya, H; Hilala, T; Alama, K; Joyc, C; Ahsan, F; Multi-purposable filaments of HPMC for 3D printing of medications with tailored drug release and timed-absorption, *International Journal of. Pharmaceutics*,544(2018).
 13. Caccavo, D; Cascone, S, Lamberti, G; Barba, A.A. ; Larsson, A, Swellable Hydrogel-based Systems for controlled Drug Delivery, in *Smart drug delivery system*, INTECH(2016).
 14. Caccavo, D; Vietri, A; Lamberti, G; Barba, A.A; Larsson, A, Modeling the mechanics and the transport phenomena in hydrogels, Chapter 12
 15. Siepmann, J; Peppas, N.A.; Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC), *Advanced drug delivery reviews*,48(2001).
 16. Caccavo, D; Lamberti, G; Barba, A.A, Mechanics and drug release from poroviscoelastic hydrogels: Experiments and modeling, *European Journal of Pharmaceutics and Biopharmaceutics*,152(2020).
 17. Caccavo, D; Cascone, S; Lamberti, G and Barba, A.A, Hydrogels: experimental characterization and mathematical modelling of their mechanical and diffusive behavior, *Royal society of Chemistry* (2018).
 18. Caccavo, D, Analysis and modeling of the behavior of hydrogels-based systems for biomedical and agro-food applications (PhD Thesis).
 19. Gurtin, M. E., Fried, E., & Anand, L, *The mechanics and thermodynamics of Continua*, New York: Cambridge University Press (2010).
 20. Caccavo, D; Lamberti, G; PoroViscoElastic model to describe hydrogels' behavior, *Material science and engineering:C*,76(2017).
 21. FLORY, P. J. *Principles of Polymer Chemistry*, Cornell University (1953)
 22. Lucantonio, A; Nardinocchi, P; and Teresi, *Multiphysics Modeling of Swelling Gels* (2012)
 23. Bajwa, G.S; Sammon, C; Timmins, B; D. Melia, C; Molecular and mechanical properties of hydroxypropyl methylcellulose solutions during the sol: gel transition, *Polymer*,50 (2009)
 24. Chen, H.H; Rheological properties of HPMC enhanced Surimi analyzed by small- and large-strain tests: I. The effect of concentration and temperature on HPMC flow properties, *Food hydrocolloids*,22 (2008)
-

-
25. Sinko, C; P. Smith, D and R. Nixon, P ,Mechanical characterization of hydroxypropyl methylcellulose:modulus determination from indentation loading profiles, International Journal of Pharmaceutics,81(1992)
 26. Qijun Li a, Haoyang Wen a, Danyang Jia c, Xiaoying Guan a, Hao Pan d, Yue Yang a, Shihui Yu a, Zhihong Zhu a, Rongwu Xiang b, *, Weisan Pan, Preparation and investigation of controlled-release glipizide novel oral device with three-dimensional printing, International Journal of Pharmaceutics,525(2017)
-

Eventuali ringraziamenti (su pagina dispari)

Aggiungere in fine una pagina (pari) completamente bianca